Shares of ObsEva SA (NASDAQ:OBSV) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Brokers have set a one year consensus target price of $22.00 for the company, according to Zacks. Zacks has also assigned ObsEva SA an industry rank of 99 out of 265 based on the ratings given to related companies.

OBSV has been the subject of a number of recent research reports. Leerink Swann restated an “outperform” rating and set a $18.00 price objective on shares of ObsEva SA in a research note on Wednesday, August 16th. HC Wainwright set a $27.00 price objective on shares of ObsEva SA and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Finally, Zacks Investment Research downgraded shares of ObsEva SA from a “hold” rating to a “sell” rating in a research note on Saturday, August 19th.

Several institutional investors have recently bought and sold shares of the company. NEA Management Company LLC acquired a new position in ObsEva SA during the first quarter worth approximately $34,734,000. Sphera Funds Management LTD. boosted its stake in shares of ObsEva SA by 9.7% in the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock worth $1,979,000 after buying an additional 20,411 shares during the last quarter. Sectoral Asset Management Inc boosted its stake in shares of ObsEva SA by 181.9% in the second quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after buying an additional 137,331 shares during the last quarter. VHCP Management II LLC purchased a new stake in shares of ObsEva SA during the second quarter worth about $1,283,000. Finally, UBS Oconnor LLC purchased a new stake in shares of ObsEva SA during the first quarter worth about $1,017,000. Institutional investors own 48.46% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Zacks: ObsEva SA (OBSV) Given Consensus Recommendation of “Strong Buy” by Analysts” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.watchlistnews.com/zacks-obseva-sa-obsv-given-consensus-recommendation-of-strong-buy-by-analysts/1530195.html.

ObsEva SA (NASDAQ OBSV) traded down 7.50% during trading on Tuesday, reaching $6.41. The company had a trading volume of 58,447 shares. The stock’s market cap is $182.66 million. The company has a 50-day moving average price of $7.92 and a 200 day moving average price of $8.92. ObsEva SA has a 52-week low of $5.00 and a 52-week high of $14.69.

ObsEva SA (NASDAQ:OBSV) last announced its earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.13. During the same period in the previous year, the business earned ($0.30) EPS. On average, analysts anticipate that ObsEva SA will post ($2.32) earnings per share for the current year.

About ObsEva SA

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Get a free copy of the Zacks research report on ObsEva SA (OBSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with Analyst Ratings Network's FREE daily email newsletter.